{"organizations": [], "uuid": "df27642152a0a88382393af24603361a8067ce24", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-merck-lungcancer/merck-kgaa-pfizers-immunotherapy-fails-in-lung-cancer-trial-idUKKCN1FZ1PN", "country": "US", "domain_rank": 408, "title": "Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-15T15:35:00.000+02:00", "replies_count": 0, "uuid": "df27642152a0a88382393af24603361a8067ce24"}, "author": "", "url": "https://uk.reuters.com/article/us-merck-lungcancer/merck-kgaa-pfizers-immunotherapy-fails-in-lung-cancer-trial-idUKKCN1FZ1PN", "ord_in_thread": 0, "title": "Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial", "locations": [], "entities": {"persons": [{"name": "bavencio", "sentiment": "none"}, {"name": "edward taylor", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}], "locations": [{"name": "frankfurt", "sentiment": "none"}], "organizations": [{"name": "merck kgaa", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "ludwig burger", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 15, 2018 / 1:35 PM / Updated 26 minutes ago Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial Reuters Staff 1 Min Read FRANKFURT (Reuters) - Merck KGaA and Pfizerâ€™s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. The results revealed on Thursday mark another setback for a drug that is a late starter in the rapidly evolving field of cancer immunotherapies. Merck shares turned negative following the news, trading 1.1 percent lower. Reporting by Ludwig Burger; Editing by Edward Taylor", "external_links": [], "published": "2018-02-15T15:35:00.000+02:00", "crawled": "2018-02-15T16:04:03.035+02:00", "highlightTitle": ""}